Specific detection of CD133-positive tumor cells with iron oxide nanoparticles labeling using noninvasive molecular magnetic resonance imaging

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 6997-7018

  Chen, Ya Wen ^a,b   Liou, Gunn Guang ^a   Pan, Huay Ben ^c,d   Tseng, Hui Hwa ^c,d   Hung, Yu Ting ^c   Chou, Chen Pin ^c,d,e,f  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e FOOYIN UNIVERSITY   (Taiwan)

^f NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

CD133; Molecular imaging; MRI; USPIO; USPIO CD133 Ab

Indexed keywords

CD133 ANTIGEN; CD133 ANTIGEN ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE CONJUGATE; REACTIVE OXYGEN METABOLITE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; ANTIBODY; DEXTRAN; ETHYLNITROSOUREA; FERUMOXTRAN-10; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MAGNETITE NANOPARTICLE; PEPTIDE; PROM1 PROTEIN, HUMAN; PROM1 PROTEIN, MOUSE; PROM1 PROTEIN, RAT; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN TUMOR; CELL LABELING; CELL PROLIFERATION; CONJUGATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MARKER; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR DYNAMICS; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RAT; TUMOR CELL; TUMOR XENOGRAFT; ANIMAL; BRAIN NEOPLASMS; CELL DEATH; CHEMISTRY; DRUG SCREENING; HT-29 CELL LINE; METABOLISM; PATHOLOGY; PROCEDURES; STAINING;

AC133 ANTIGEN; ANIMALS; ANTIBODIES; ANTIGENS, CD; BRAIN NEOPLASMS; CELL DEATH; DEXTRANS; ETHYLNITROSOUREA; GLYCOPROTEINS; HT29 CELLS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MICE; MOLECULAR IMAGING; PEPTIDES; PROTEIN BINDING; RATS; STAINING AND LABELING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84947056864     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S86592     Document Type: Article

References (72)

1. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature. 2005;435(7046):1267–1270.
2. Huntly BJ, Gilliland DG. Cancer biology: summing up cancer stem cells. Nature. 2005;435(7046):1169–1170.
3. Pfenninger CV, Roschupkina T, Hertwig F, et al. CD133 is not pres­ent on neurogenic astrocytes in the adult subventricular zone, but on embryonic neural stem cells, ependymal cells, and glioblastoma cells. Cancer Res. 2007;67(12):5727–5736.
4. Yi JM, Tsai HC, Glockner SC, et al. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res. 2008;68(19):8094–8103.
5. Miraglia S, Godfrey W, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecu­lar cloning. Blood. 1997;90(12):5013–5021.
6. Bhatia M. AC133 expression in human stem cells. Leukemia. 2001;15(11):1685–1688.
7. Corbeil D, Roper K, Hellwig A, et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem. 2000;275(8):5512–5520.
8. Rafii S. Circulating endothelial precursors: mystery, reality, and promise. J Clin Invest. 2000;105(1):17–19.
9. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18):5821–5828.
10. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396–401.
11. Yin S, Li J, Hu C, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 2007;120(7):1444–1450.
12. Yang K, Chen XZ, Zhang B, et al. Is CD133 a biomarker for cancer stem cells of colorectal cancer and brain tumors? A meta-analysis. Int J Biol Markers. 2011;26(3):173–180.
13. Xia P. Surface markers of cancer stem cells in solid tumors. Curr Stem Cell Res Ther. 2013;9(2):102–111.
14. Moghbeli M, Moghbeli F, Forghanifard MM, Abbaszadegan MR. Cancer stem cell detection and isolation. Med Oncol. 2014;31(9):69.
15. Maitland NJ, Collins AT. Cancer stem cells – a therapeutic target? Curr Opin Mol Ther. 2010;12(6):662–673.
16. Allegra A, Alonci A, Penna G, et al. The cancer stem cell hypothesis: a guide to potential molecular targets. Cancer Invest. 2014;32(9):470–495.
17. Islam T, Josephson L. Current state and future applications of active targeting in malignancies using superparamagnetic iron oxide nano­particles. Cancer Biomark. 2009;5(2):99–107.
18. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology. 1990;175(2):489–493.
19. Tanimoto A, Oshio K, Suematsu M, Pouliquen D, Stark DD. Relaxation effects of clustered particles. J Magn Reson Imaging. 2001;14(1):72–77.
20. Gossuin Y, Gillis P, Hocq A, Vuong QL, Roch A. Magnetic resonance relaxation properties of superparamagnetic particles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1(3):299–310.
21. Himmelreich U, Dresselaers T. Cell labeling and tracking for experi­mental models using magnetic resonance imaging. Methods. 2009;48(2):112–124.
22. Corot C, Robert P, Idee JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev. 2006;58(14):1471–1504.
23. Zhang C, Jugold M, Woenne EC, et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res. 2007;67(4):1555–1562.
24. Baio G, Fabbi M, de Totero D, et al. Magnetic resonance imaging at 1.5T with immunospecific contrast agent in vitro and in vivo in a xenotransplant model. MAGMA. 2006;19(6):313–320.
25. Baio G, Fabbi M, Salvi S, et al. Two-step in vivo tumor targeting by biotin-conjugated antibodies and superparamagnetic nanoparticles assessed by magnetic resonance imaging at 1.5 T. Mol Imaging Biol. 2009;12(3):305–315.
26. Huang KW, Chieh JJ, Lin IT, Horng HE, Yang HC, Hong CY. Anti-CEA-functionalized superparamagnetic iron oxide nanoparticles for examin­ing colorectal tumors in vivo. Nanoscale Res Lett. 2013;8(1):413.
27. Hsieh WJ, Liang CJ, Chieh JJ, et al. In vivo tumor targeting and imag­ing with anti-vascular endothelial growth factor antibody-conjugated dextran-coated iron oxide nanoparticles. Int J Nanomedicine. 2012;7:2833–2842.
28. Yang L, Peng XH, Wang YA, et al. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res. 2009;15(14):4722–4732.
29. Shamsipour F, Zarnani AH, Ghods R, et al. Conjugation of monoclonal antibodies to super paramagnetic iron oxide nanoparticles for detec­tion of her2/neu antigen on breast cancer cell lines. Avicenna J Med Biotechnol. 2009;1(1):27–31.
30. Wang X, Wei F, Liu A, et al. Cancer stem cell labeling using poly(L-lysine)-modified iron oxide nanoparticles. Biomaterials. 2012;33(14):3719–3732.
31. Wong DY, Chang KW, Chen CF, Chang RC. Characterization of two new cell lines derived from oral cavity human squamous cell carcinomas–OC1 and OC2. J Oral Maxillofac Surg. 1990;48(4):385–390.
32. Jiang W, Yang HC, Yang SY, et al. Preparation and properties of superparamagnetic nanoparticles with narrow size distribution and biocompatible. J Magn Magn Mater. 2004;283(2–3):210–214.
33. Horng HE, Yang SY, Huang YW, Jiang WQ, Hong CY, Yang HC. Nanomagnetic particles for SQUID-based magnetically labeled immu­noassay. IEEE Trans Appl Supercond. 2005;15(2):668–671.
34. Yang SY, Jian ZF, Horng HE, et al. Dual immobilization and mag­netic manipulation of magnetic nanoparticles. J Magn Magn Mater. 2008;320(21):2688–2691.
35. Huang KW, Yang SY, Horng HE, et al. Time-evolution contrast of target MRI using high-stability antibody functionalized magnetic nanoparticles: an animal model. J Nanomater. 2014;2014:351848.
36. Hong C-Y, Chen WS, Jian ZF, et al. Wash-free immunomagnetic detection for serum through magnetic susceptibility reduction. Appl Phys Lett. 2007;90(7):074105.
37. Yang CC, Huang KW, Yang SY, et al. Development for high-accuracy in vitro assay of vascular endothelial growth factor using nanomagneti­cally labeled immunoassay. J Nanomater. 2013;2013:695276.
38. Yang CC, Yang SY, Ho CS, Chang JF, Liu BH, Huang KW. Develop­ment of antibody functionalized magnetic nanoparticles for the immu­noassay of carcinoembryonic antigen: a feasibility study for clinical use. J Nanobiotechnol. 2014;12(1):44.
39. Chen FJ, Lee KW, Lai CC, et al. Structure of native oligomeric Sprouty2 by electron microscopy and its property of electroconductivity. Biochem Biophys Res Commun. 2013;439(3):351–356.
40. Pawelczyk E, Arbab AS, Pandit S, Hu E, Frank JA. Expression of transferrin receptor and ferritin following ferumoxides-protamine sulfate labeling of cells: implications for cellular magnetic resonance imaging. NMR Biomed. 2006;19(5):581–592.
41. Chen YW, Tsai MY, Pan HB, Tseng HH, Hung YT, Chou CP. Gadoxetic acid-enhanced MRI and sonoelastography: non-invasive assessments of chemoprevention of liver fibrosis in thioacetamide-induced rats with sho-saiko-to. PLoS One. 2014;9(12):e114756.
42. Stahn R, Rose S, Sanborn S, West G, Herschman H. Effects of nerve growth factor administration of N-ethyl-N-nitrosourea carcinogenesis. Brain Res. 1975;96(2):287–298.
43. Habs M, Schmahl D. Influence of five different postnatal lifelong treatments on the transplacental carcinogenicity of ethylnitrosourea in Sprague-Dawley rats. Cancer Lett. 1976;2(2):93–100.
44. Ieta K, Tanaka F, Haraguchi N, et al. Biological and genetic charac­teristics of tumor-initiating cells in colon cancer. Ann Surg Oncol. 2008;15(2):638–648.
45. Sharifi S, Behzadi S, Laurent S, Forrest ML, Stroeve P, Mahmoudi M. Toxicity of nanomaterials. Chem Soc Rev. 2012;41(6):2323–2343.
46. Kim JE, Shin JY, Cho MH. Magnetic nanoparticles: an update of application for drug delivery and possible toxic effects. Arch Toxicol. 2012;86(5):685–700.
47. Rosenblum LT, Kosaka N, Mitsunaga M, Choyke PL, Kobayashi H. In vivo molecular imaging using nanomaterials: general in vivo char­acteristics of nano-sized reagents and applications for cancer diagnosis. Mol Membr Biol. 2010;27(7):274–285.
48. Peng XH, Qian X, Mao H, et al. Targeted magnetic iron oxide nanopar­ticles for tumor imaging and therapy. Int J Nanomedicine. 2008;3(3):311–321.
49. Jiang T, Zhang C, Zheng X, et al. Noninvasively characterizing the different alphavbeta3 expression patterns in lung cancers with RGD-USPIO using a clinical 3.0T MR scanner. Int J Nanomedicine. 2009;4:241–249.
50. Shevtsov MA, Nikolaev BP, Yakovleva LY, et al. Superparamagnetic iron oxide nanoparticles conjugated with epidermal growth factor (SPION-EGF) for targeting brain tumors. Int J Nanomedicine. 2014;9:273–287.
51. Sun R, Dittrich J, Le-Huu M, et al. Physical and biological charac­terization of superparamagnetic iron oxide- and ultrasmall superpara­magnetic iron oxide-labeled cells: a comparison. Invest Radiol. 2005;40(8):504–513.
52. Guo Q, Liu Y, Xu K, Ren K, Sun W. Mouse lymphatic endothelial cell targeted probes: anti-LYVE-1 antibody-based magnetic nanoparticles. Int J Nanomedicine. 2013;8:2273–2284.
53. Chen H, Wang L, Yu Q, et al. Anti-HER2 antibody and ScFvEGFR-conjugated antifouling magnetic iron oxide nanoparticles for targeting and magnetic resonance imaging of breast cancer. Int J Nanomedicine. 2013;8:3781–3794.
54. Wang X, Xing X, Zhang B, Liu F, Cheng Y, Shi D. Surface engineered antifouling optomagnetic SPIONs for bimodal targeted imaging of pancreatic cancer cells. Int J Nanomedicine. 2014;9:1601–1615.
55. Moore A, Medarova Z, Potthast A, Dai G. In vivo targeting of underg­lycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res. 2004;64(5):1821–1827.
56. Simberg D, Duza T, Park JH, et al. Biomimetic amplification of nano­particle homing to tumors. Proc Natl Acad Sci U S A. 2007;104(3):932–936.
57. Al Faraj A, Shaik AS, Afzal S, Al Sayed B, Halwani R. MR imaging and targeting of a specific alveolar macrophage subpopulation in LPS-induced COPD animal model using antibody-conjugated magnetic nanoparticles. Int J Nanomedicine. 2014;9:1491–1503.
58. Towner RA, Smith N, Tesiram YA, et al. In vivo detection of c-MET expression in a rat hepatocarcinogenesis model using molecularly tar­geted magnetic resonance imaging. Mol Imaging. 2007;6(1):18–29.
59. Thorek DL, Chen AK, Czupryna J, Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng. 2006;34(1):23–38.
60. Arbab AS, Yocum GT, Rad AM, et al. Labeling of cells with ferumoxides-protamine sulfate complexes does not inhibit function or differentiation capacity of hematopoietic or mesenchymal stem cells. NMR Biomed. 2005;18(8):553–559.
61. Wang YX. Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant Imaging Med Surg. 2012;1(1):35–40.
62. Schlachter EK, Widmer HR, Bregy A, et al. Metabolic pathway and distribution of superparamagnetic iron oxide nanoparticles: in vivo study. Int J Nanomedicine. 2011;6:1793–1800.
63. Chertok B, David AE, Yang VC. Brain tumor targeting of magnetic nano­particles for potential drug delivery: effect of administration route and magnetic field topography. J Control Release. 2011;155(3):393–399.
64. Fleige G, Nolte C, Synowitz M, Seeberger F, Kettenmann H, Zimmer C. Magnetic labeling of activated microglia in experimental gliomas. Neoplasia. 2001;3(6):489–499.
65. Prokop A, Davidson JM. Nanovehicular intracellular delivery systems. J Pharm Sci. 2008;97(9):3518–3590.
66. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res. 2010;62(2):90–99.
67. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol. 2001;11(11):2319–2331.
68. Huang X, Peng X, Wang Y, Shin DM, El-Sayed MA, Nie S. A reex­amination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. ACS Nano. 2010;4(10):5887–5896.
69. Chertok B, Moffat BA, David AE, et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials. 2008;29(4):487–496.
70. Sun J, Zhang C, Liu G, et al. A novel mouse CD133 binding-peptide screened by phage display inhibits cancer cell motility in vitro. Clin Exp Metastasis. 2012;29(3):185–196.
71. Gonzales NR, De Pascalis R, Schlom J, Kashmiri SV. Minimizing the immunogenicity of antibodies for clinical application. Tumour Biol. 2005;26(1):31–43.
72. Jalalian SH, Taghdisi SM, Shahidi Hamedani N, et al. Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo. Eur J Pharm Sci. 2013;50(2):191–197.